23andMe says TTAM Research Institute, a nonprofit backed by Anne Wojcicki, is the new buyer for the company's assets, offering $305M and topping Regeneron's bid
Context & Ripple Effects
The proposed buyer has changed twice in quick succession: Regeneron had won the bankruptcy auction with a $256M asset deal, before a second auction opened around a $305M bid led by Anne Wojcicki.
The reversal follows Wojcicki’s earlier effort to take 23andMe private after its valuation decline, tying the asset sale back to the founder’s longstanding attempt to regain control of the business.
First-order effects
- TTAM Research Institute becomes the stated buyer at $305M, displacing Regeneron’s earlier $256M winning bid for 23andMe’s assets.
- Regeneron loses the announced acquisition path, while TTAM and its backer Anne Wojcicki take responsibility for completing the asset purchase.
Second-order effects
- The higher offer establishes a materially different owner for 23andMe’s assets: a nonprofit backed by the former CEO rather than a pharmaceutical company.
- The auction outcome raises the value required for any remaining challenge to TTAM’s bid and gives 23andMe’s stakeholders a higher proposed recovery than the prior deal.
Third-order effects
- If founder-backed nonprofit ownership is completed, it would show that strategically important consumer-genetics assets can move outside both public-market ownership and direct pharmaceutical acquisition.
- The case underscores how distressed data-rich platforms can draw competing buyers with different strategic rationales, making ownership transitions—not just operating performance—a central industry question.
The trend: 23andMe’s sale is part of a broader shift in which distressed, data-rich consumer platforms are being repositioned through buyer-led ownership changes rather than conventional public-company recovery.